Helicobacter pylor (H pylori), a Gram‐negative, microaerobic human pathogen, has been found to be involved in many gastroduodenal diseases. Accurate diagnosis of H pylori infection is a vital part of the effective management of gastroduodenal diseases. Circulating microRNAs (miRNAs) have shown the potential to be used as noninvasive biomarkers for the diagnosis of infectious diseases. The aim of this study was to explore plasma miRNAs as noninvasive biomarkers for H pylori infection. We performed a plasma miRNA expression profile using Illumina high‐throughput sequencing and validated the levels of differentially expressed miRNAs in the plasma of 63 H pylori‐infected patients and 41 healthy volunteers by quantitative real‐time polymerase chain reaction (qRT‐PCR). The sequencing results showed that 37 miRNAs were upregulated in the H pylori‐infected patients compared with that in the healthy volunteers, while six miRNAs were downregulated. qRT‐PCR and receiver operator characteristic analysis suggested that the expression of miR‐28‐3p, miR‐143‐3p, miR‐151a‐3p, and miR‐148a‐3p were closely associated with H pylori infection. Therefore, the four plasma miRNA panels mentioned above could serve as promising noninvasive biomarkers of H pylori infection.
Non-small cell lung cancer (NSCLC) is a major cause of death associated with lung cancer, taking up over 85% of all lung cancers. 1 The survival of patients can be prolonged by diagnosing and treating the disease in the early stage. Nevertheless, the potential mechanism by which lung cancer evolves remains undocumented. Advances made in RNA research recently have contributed to identification
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.